A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Description

The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then repeat the cognitive tasks. The researchers will compare the results at the end of the treatment period to the baseline to see if there have been any changes in performance. Additionally, several safety measures will be collected throughout the study (blood pressure, physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.

Conditions

Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then repeat the cognitive tasks. The researchers will compare the results at the end of the treatment period to the baseline to see if there have been any changes in performance. Additionally, several safety measures will be collected throughout the study (blood pressure, physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.

An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Condition
Cognitive Impairment Associated With Schizophrenia (CIAS)
Intervention / Treatment

-

Contacts and Locations

Culver City

Recognify Research Site, Culver City, California, United States, 90230

Garden Grove

Collaborative Neuroscience Research, Garden Grove, California, United States, 92845

Lafayette

Recognify Research Site, Lafayette, California, United States, 94549

Oceanside

Recognify Research Site, Oceanside, California, United States, 92056

Orange

Recognify Research Site, Orange, California, United States, 92868

Torrance

Recognify Research Site, Torrance, California, United States, 90502

Clermont

Recognify Research Site, Clermont, Florida, United States, 34711

Hialeah

Recognify Research Site, Hialeah, Florida, United States, 33016

Miami Lakes

Recognify Research Site, Miami Lakes, Florida, United States, 33016

Miami

Recognify Research Site, Miami, Florida, United States, 33135

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of schizophrenia, per Diagnostic and Statistical Manual (DSM) 5, with a duration of at least 6 months
  • * Positive and Negative Symptoms Severity Score (PANSS) of less than or equal to 80 (inclusive)
  • * Currently treated on a single atypical antipsychotic (other than clozapine) at a stable dose and clinically stable for at least 6 weeks before randomization
  • * Clinical Global Impression - Severity score \< 5.
  • * Body mass index (BMI) \<= 40.0 kg/m\^2 at screening
  • * Participant has reliable housing that is not expected to change during the study period with no expected significant life events that could affect study outcomes throughout entire study period.
  • * Sufficient fluency in English to understand and complete study instructions and assessments
  • * History of hospitalization for medical indication or psychiatric hospitalization within 3 months prior to screening.
  • * Participants who present a serious risk of suicide, as evidenced by a) "yes" on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) and meeting these criteria within the past 6 months, or b) posing a significant suicide risk in the Investigator's judgement.
  • * Participants who present a risk of serious harm to others, as evidence by any history within the past 2 years and any expressed homicidal ideation (with or without plan).
  • * Current diagnosis of another major psychiatric disorder, intellectual disability, or any major neurological disease, brain injury, epilepsy, or severe brain trauma.
  • * Evidence or history of significant cognitive impairment, other than associated with schizophrenia, that in the judgement of the Investigator or Sponsor would confound interpretation of study data or prevent safe and satisfactory completion of the study protocol.
  • * Meets criteria for moderate to severe substance/drug abuse disorder (including alcohol) per DSM-5 within the last 6 months prior to informed consent or a positive alcohol breath test or urine test for drugs of abuse at either Screening or Randomization Visits (except for benzodiazepines taken according to prescription and as an ongoing, stable regimen).
  • * Participant has undergone electroconvulsive therapy within the past 12 months.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Recognify Life Sciences,

Gary Walker, PhD, STUDY_DIRECTOR, Recognify Life Sciences

Study Record Dates

2025-07